Business & Economics

Rakuten Medical and Merck KGaA sign Multi-year Agreement for ASP-1929

Rakuten Medical and Merck KGaA, Darmstadt, Germany have signed a multi-year agreement under which Merck provides cetuximab to Rakuten...
New York Stock Exchange (released under Public Domain license. Photo courtesy 2020 Jean Beaufort.

ADC Therapeutics Completes U.S. $ 267 Million Initial Public Offering

Earlier today, New Ventures Funds, a venture fund targeting investments in companies across healthcare and life sciences, confirmed that...
Suzhou, china, 苏州,中国

First ‘Intelligent Ligase-dependent Conjugation’ Enabling ADC Receives FDA IND Clearance

This week, GeneQuantum Healthcare, a Suzhou, China-based developer of bioconjugate drugs, confirmed that the company has received an Investigational...

Adagene and Tanabe Sign Strategic ADC Development Agreement

Adagene, a Suzhou (China) and San Francisco, California, based clinical-stage biotech company developing novel antibody discovery and engineering technologies...
Research associate at Genmab, Cell culturing. Photo courtesy: 2020 Genmab/Tuala Hjarnø and Torkil Stavdal

AbbVie and Genmab Sign U.S. $ 3.9 Billion Development Agreement

Chicago-based AbbVie and Genmab, headquartered in Copenhagen, Denmark, have entered into a broad oncology development program in which the...
Featured Image: MabPlex Building, Yantai, Shandong, China. Courtesy: © 2017 MabPlex. Used with permission.

MabPlex International Secures Series B Financing

MabPlex International, a Contract Development and Manufacturing Organization (CDMO) based in Yantai, the Shandong Peninsula in northeastern Shandong province,...

LegoChem Biosciences and Iksuda Sign Multi-Target Research Collaboration and License Agreement

In a statement, South Korean LegoChen Biosciences and UK's Iksuda Therapeutics confirmed that the companies have entered into a...

ImmunoGen Initiates Pivotal Trial Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer

Biotech company ImmunoGen, leveraging the targeting ability of antibodies to deliver cytotoxic drugs directly to cancer cells by developing...
Ajinomoto Bio-Pharma Services has established a high-containment bioconjugate manufacturing facility for the production and fill and finish of Highly Potent Active Pharmaceutical Intermediates (HPAPI) and Antibody Drug Conjugates (ADC). The facility, developed by SKAN AG, has been designed for safe handling and manipulation of very low OEL compounds (down to 1 ng/m3) while maintaining aseptic conditions and cGMP compliance. Photo courtesy: © 2020 Ajinomoto Bio-Pharma.

Trio Pharmaceuticals and Ajinomoto Ink Agreement to Develop First-in-class Dual Functionality ADC

Patients being treated for cancer may often benefit from a combination of systemic cancer chemotherapies. The rationale for the...

Everest Medicines’ Licensing Partner Immunomedics Receives FDA Accelerated Approval for Sacituzumab Govitecan for the...

Everest Medicines' U.S.-based licensing partner Immunomedics earlier today confirmed that the U.S. Food and Drug Administration (FDA) has approved...